Avacincaptad pegol helps patients with GA maintain driving eligibility

Treatment with avacincaptad pegol (ACP) 2mg in patients with geographic atrophy (GA) significantly reduces the likelihood of progressing to vision impairments that would restrict or disqualify them from driving, compared to a sham treatment, according to a presentation by Seenu Hariprasad, MD at ASRS 2024.

“As you know from interactions with your patients, the progressive loss of vision associated with GA heavily impacts their quality of life and independence,” Dr Hariprasad said.

This post hoc analysis evaluated the progression to loss of driving eligibility among patients in the GATHER1 and GATHER2 trials.

Among patients with a baseline BCVA of ≥75 letters, 12.3% of ACP 2mg-treated patients versus 20.4% of sham-treated patients experienced BCVA ≤65 letters at any post-baseline visit. For those with a baseline BCVA of ≥70 letters, 25.0% of ACP-treated patients versus 23.7% of sham-treated patients had BCVA ≤60 letters at any post-baseline visit.

During the presentation, Dr Hariprasad concluded that the results “suggest that ACP 2mg may be beneficial for postponing driving restrictions or the loss of driving eligibility in people with higher BCVA at baseline.”

Reference
Hariprasad S, et al. Maintenance of Driving Eligibility in Patients With Geographic Atrophy From the GATHER1 and GATHER2 Clinical Trials: A Post Hoc Analysis. Presented at: ASRS 42nd Annual Meeting: July 17–20, 2024.